The mRNA unicorn Moderna has more early-stage human data it wants to show off — reaching new peaks in proving the potential
The whole messenger RNA field has attracted billions of dollars in public and private investor cash gambled on the prospect of getting in on the ground floor. And this morning Boston-based Moderna, one of the leaders in the field, wants to show off a few more of the cards it has to play to prove to you that they’re really in the game.
The whole hand, of course, has yet to be dealt. And there’s no telling who gets to walk with a share of the pot. But any cards on display at this point — especially after being accused of keeping its deck under lock and key — will attract plenty of attention from some very wary, and wired, observers.
“In terms of the complexity and unmet need,” says Tal Zaks, the chief medical officer, “this is peak for what we’ve accomplished.”
Moderna has two Phase I studies it wants to talk about now.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.